The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
One-Sample Multiple Testing Procedure for Phase II Clinical Trials
Fleming, T. R. (1982) · Biometrics · doi:10.2307/2530297 · Cited by 1,003
Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · cited 1×
“The 35% response rate in WHO grade III astrocytoma (anaplastic astrocytoma) [5] in comparison with a 6–8% response rate in grade IV tumours (glioblastoma multiforme) [6, 7] suggests a possible trend of increasing efficacy in lower grade tumours previously noted for nitrosourea-containing chemotherapy [8].”
ResultSelf-citationYung, W. K. A., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R., Olson, J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 761
Self-citationCairncross, G., Macdonald, D., Ludwin, S., Lee, D., Cascino, T., Buckner, J., Fulton, D., Dropcho, E., Stewart, D., & Schold, C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2013 · Cited by 442
Karim, A. B. M. F., Afra, D., Cornu, P., Bleehan, N., Schraub, S., De Witte, O., Darcel, F., Stenning, S., Pierart, M., & Van Glabbeke, M. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02692-x · Cited by 389
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372 · cited 2×
“The 35% response rate in WHO grade III astrocytoma (anaplastic astrocytoma) [5] in comparison with a 6–8% response rate in grade IV tumours (glioblastoma multiforme) [6, 7] suggests a possible trend of increasing efficacy in lower grade tumours previously noted for nitrosourea-containing chemotherapy [8].”
MethodResultSelf-citationOsoba, D., Aaronson, N. K., Muller, M., Sneeuw, K., Hsu, M. A., Yung, W. K. A., Brada, M., & Newlands, E. (1996) · Quality of Life Research · doi:10.1007/bf00435979 · Cited by 343
Self-citationLong-term outcome of low-grade oligodendroglioma and mixed glioma
Olson, J. D., Riedel, E., & DeAngelis, L. M. (2000) · Neurology · doi:10.1212/wnl.54.7.1442 · Cited by 340
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
Quinn, J. A., Reardon, D. A., Friedman, A. H., Rich, J. N., Sampson, J. H., Provenzale, J. M., McLendon, R. E., Gururangan, S., Bigner, D. D., Herndon, J. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.009 · Cited by 258
Buckner, J. C., Gesme, D., O’Fallon, J. R., Hammack, J. E., Stafford, S., Brown, P. D., Hawkins, R., Scheithauer, B. W., Erickson, B. J., Levitt, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.023 · Cited by 249
Lote, K., Egeland, T., Hager, B., Stenwig, B., Skullerud, K., Berg-Johnsen, J., Storm-Mathisen, I., & Hirschberg, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.9.3129 · Cited by 236
Low-grade oligodendroglioma responds to chemotherapy
Mason, W. P., Krol, G. S., & DeAngelis, L. M. (1996) · Neurology · doi:10.1212/wnl.46.1.203 · Cited by 218
Brada, M., Judson, I., Beale, P., Moore, S., Reidenberg, P., Statkevich, P., Dugan, M., Batra, V, & Cutler, D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690802 · Cited by 208
Self-citationvan den Bent, M. J., Kros, J. M., Heimans, J. J., Pronk, L. C., van Groeningen, C. J., Krouwer, H. G. J., Taphoorn, M. J. B., Zonnenberg, B. A., Tijssen, C. C., Twijnstra, A., et al. (1998) · Neurology · doi:10.1212/wnl.51.4.1140 · Cited by 206
The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy
Glass, J., Hochberg, F. H., Gruber, M. L., et al. (1992) · Journal of neurosurgery · doi:10.3171/jns.1992.76.5.0741 · Cited by 187
Eyre, H. J., Crowley, J. J., Townsend, J. J., Eltringham, J. R., Morantz, R. A., Schulman, S. F., Quagliana, J. M., & Al-Sarraf, M. (1993) · Journal of Neurosurgery · doi:10.3171/jns.1993.78.6.0909 · Cited by 167
PCV Chemotherapy for Recurrent Oligodendrogliomas and Oligoastrocytomas
Soffietti, R., Rudà, R., Bradac, G. B., & Schiffer, D. (1998) · Neurosurgery · doi:10.1097/00006123-199811000-00035 · Cited by 161
Salvage chemotherapy for oligodendroglioma
Peterson, K., Paleologos, N. A., Forsyth, P. D., Macdonald, D. R., Cairncross, J. G., & _, _. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.85.4.0597 · Cited by 74
Rajan, B., Ross, G., Lim, C. C., Ashley, S., Goode, D., Traish, D., & Brada, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00248-4 · Cited by 66
Self-citationTreatment of oligodendroglioma: An update
Paleologos, N. A., & Cairncross, J. G. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.61 · Cited by 30
Cited by
van den Bent, M., Afra, D., de Witte, O., Hassel, M. B., Schraub, S., Hoang-Xuan, K., Malmström, P.-O., Collette, L., Piérart, M., Mirimanoff, R., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67070-5 · Cited by 1,035
Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management
van Breemen, M. S., Wilms, E. B., & Vecht, C. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70103-5 · Cited by 913
van den Bent, M., Wefel, J., Schiff, D., Taphoorn, M., Jaeckle, K., Junck, L., Armstrong, T., Choucair, A., Waldman, A., Gorlia, T., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70057-2 · Cited by 645
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
Houillier, C., Wang, X., Kaloshi, G., Mokhtari, K., Guillevin, R., Laffaire, J., Paris, S., Boisselier, B., Idbaih, A., Laigle-Donadey, F., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f96282 · Cited by 535
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang‐Xuan, K., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03151.x · Cited by 505
Metadata
- Authors
- Brada, M., Viviers, L., Abson, C., Hines, F., Britton, J., Ashley, S., Sardell, S., Traish, D., Gonsalves, A., Wilkins, P., & Westbury, C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2003-12
- Volume
- 14
- Issue
- 12
- Pages
- 1715-1721
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2171212160
- Cited by
- 261
- References
- 21
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.